Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Abbott Laboratories (ABT – Research Report) and Corbus Pharmaceuticals (CRBP – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Cigna (CI)

Bernstein analyst Lance Wilkes maintained a Hold rating on Cigna today and set a price target of $346.00. The company’s shares closed last Wednesday at $294.57.

According to TipRanks.com, Wilkes is a 1-star analyst with an average return of -1.1% and a 47.7% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'>

Currently, the analyst consensus on Cigna is a Strong Buy with an average price target of $366.00, representing a 22.3% upside. In a report issued on October 6, Wells Fargo also maintained a Hold rating on the stock with a $354.00 price target.

See the top stocks recommended by analysts >>

Abbott Laboratories (ABT)

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories. The company’s shares closed last Wednesday at $129.45.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 5.2% and a 59.1% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Bausch + Lomb Corporation. ;'>

Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $146.20, a 14.2% upside from current levels. In a report issued on October 10, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $145.00 price target.

Corbus Pharmaceuticals (CRBP)

William Blair analyst Andy Hsieh maintained a Buy rating on Corbus Pharmaceuticals today. The company’s shares closed last Wednesday at $17.50.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 7.9% and a 45.0% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Barinthus Biotherapeutics, and Terns Pharmaceuticals. ;'>

Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $43.50, which is a 166.4% upside from current levels. In a report issued on October 7, Oppenheimer also maintained a Buy rating on the stock with a $53.00 price target.

Read More on CI:

Disclaimer & DisclosureReport an Issue

• UnitedHealth Stock (UNH) Scores Goldman Sachs’ Buy Rating, Truist Lifts Price Target
• AMD upgraded, Micron downgraded: Wall Street’s top analyst calls
• Cigna initiated with a Buy at Goldman Sachs
• Cigna price target raised to $354 from $340 at Wells Fargo
• Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role